Reimbursed orphan medicines in Bulgaria and the share of biotechnology-derived products

Biotechnology and Biotechnological Equipment

Volumn 25, Issue 2, 2011, Pages 2418-2423

  Stoimenova, Assena ^a   Manova, Manoela ^a   Savova, Alexandra ^a   Angelovska, Bistra ^b   Petrova, Guenka ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b GOCE DELCEV UNIVERSITY   (Macedonia)

Author keywords

Biotechnology derived products; Legislation; Orphan medicines; Positive drug list; Reimbursement

Indexed keywords

BIOTECHNOLOGY-DERIVED PRODUCTS; BULGARIA; EUROPEAN UNION; GENETIC ORIGIN; MEDICINAL PRODUCTS; NATIONAL MARKETS; ORPHAN MEDICINES; POSITIVE DRUG LIST; PRICE SETTING; RARE DISEASE; REGULATORY REQUIREMENTS; REIMBURSEMENT; RESOURCES ALLOCATION;

DISEASES; DRUG PRODUCTS; LAWS AND LEGISLATION; MARKETING;

BIOTECHNOLOGY;

EID: 79960394843     PISSN: 13102818     EISSN: None     Source Type: Journal    
DOI: 10.5504/bbeq.2011.0043     Document Type: Article

References (35)

1. Ayme S. and Schmidtke J. (2007) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 50(12), 1477-1483.
2. Baumevieille M., Daveluy A., Aulois-Griot M., Haramburu F (2007) Therapie. 62(1), 9-16.
3. Bulgarian Health Act (2004) State Gazette .No70/10 Aug. 2004.
4. Bulgarian Law on Medicinal Products in Human Medicine (2007) State Gazette No31/13 Apr. 2007.
5. Bulgarian National Plan for Rare Diseases (2009-2013) (genetic, birth defects and noninherited diseases), Ministry of Health, Republic of Bulgaria.
6. Chokshi D.A. (2006) PloS Med., 3(6), el36.
7. Commission Regulation (2000) Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definition of the concepts "similar medicinal product" and "clinical superiority".
8. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on rare diseases: Europe's challenges.
9. Drummond M.F., Wilson D.A., Kanavos P., Ubel P., Rovira J. (2007) Int. J. Technol. Assess. Health Care, 23(1),36-42.
10. Enzmann H. and Lutz J. (2008) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 51(5), 500-508.
11. Leufkens H.G. (2008) Drug Discov. Today, 13(15-16), 670-676.
12. Holding J. (2008) The Pharm. Journal, 280, 216-218.
13. Hudges D.A., Tunnage B., Yeo S.T. (2005) Q. J. Med., 98, 829-836.
14. Improving access to orphan medicines for all affected EU citizens (2010)
15. http://ec.europa.eu/pharmaforum/docs/pricing-orphans-en.pdf (Accessed Oct 2010)
16. Lavandeira A. (2002) Haemophilia, 8(3), 194-198.
17. List of orphan drugs in Europe (2009) Orphanet Report Series, Orphan Drugs collection, July 2009.
18. Matsui S. and Rounds D.E. (1971) Life Sci., 10,217-221.
19. Minghetti P.M., Giudici E.M., Montanari L. (2000) Pharmacol. Res., 42(1), 33-37.
20. Ministry of Health in Bulgaria (2010) The Positive Drug List, www.mh.government.bg (Assessed Oct 2010).
21. Orphan drugs and rare diseases at a glance (2007) Doc. Ref. EMEA/290072/2007, European Medicines Agency, www.ema.europa.eu
22. Parisse-Brassens J. (2010) Improving patient access to orphan drugs in Europe.
23. http://www.eurordis.org/content/improving-patient-access-orphan-drugs- europe (Assessed Oct 2010).
24. Posada M., Martin-Arribas C, Ramirez A., Villaverde A., Abitua I. (2008) An. Sist. Sanit. Navar., 31(Suppl. 2), 9-20.
25. Regulation (1999) Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan drugs.
26. Regulation (2005) Regulation 34/2005, on the provisions for funding the treatment of diseases excluded from the obligatory health insurance, State Gazette No 95/2005.
27. Regulation (2003) Regulation on criteria, conditions and rules for inclusion of medicinal products in positive list, State Gazette No 34/15.Apr.2003.
28. Segolene A. and Schmidtke J. (2007) Bundesgesundheitsblatt- Gesundheitsforschung-Gesundheitsschutz, 50(12), 1477-1483.
29. Stakisatis D., Spokiene I., Juskevicius J., Valuskas K., Baiardi P. (2007) Medicina (Kaunas), 43(6), 441-446.
30. Stolk P., Heemstra H., Leufkens H.G., Bloechl-Doum B., Heerdink E.R. (2009) Orphanet J. Rare Dis., 4,27.
31. Stolk P., Willemen M.J.C., Leufkens H.G.M. (2006) Bull. World Health Organ., 84(6), 745-751.
32. Taruscio D., Trama A., Stefanov R. (2007) Folia Med (Plovdiv), 49(1-2), 59-67.
33. Trouiller P., Torreele E., Olliaro P., White N., Foster S., Wirth D., Pecoul B. (2001) Trop. Med. Int. Health, 6(11), 945-951.
34. Watson R. (2000) BMJ, 320(7245), 1294.
35. Whyte B. (2000) Bull. World Health Organ., 78(5), 711